Switching Patients to Sialanar®
Guidance on switching patients from hyoscine or 1mg/5ml glycopyrronium bromide oral solutions to Sialanar®
Sialanar® is licensed for the symptomatic treatment of severe sialorrhoea in children and adolescents aged 3 years and older with chronic neurological disorders.1 Adverse event reporting information can be found at the bottom of the page.
Dose table for children and adolescents with normal renal function (glycopyrronium bromide)1
Click on the patient's weight below to find the recommended dose
13-17 kg
18-22 kg
23-27 kg
28-32 kg
33-37 kg
38-42 kg
43-47 kg
≥48 kg
13-17 kg
-
Dose Level 1
~16 mcg/kg
0ml*
-
Dose Level 2
~32 mcg/kg
0ml*
-
Dose Level 3
~48 mcg/kg
0ml*
-
Dose Level 4
~64 mcg/kg
0ml*
-
Dose Level 5
~80 mcg/kg
0ml*
* Maximum individual dose in this weight range.
Dose table for children and adolescents with mild to moderate renal impairment (eGFR <90 - ≥30 ml/min/1.73m2) (glycopyrronium bromide)1
Click on the patient's weight below to find the recommended dose
13-17 kg
18-22 kg
23-27 kg
28-32 kg
33-37 kg
38-42 kg
43-47 kg
≥48 kg
13-17 kg
-
Dose Level 1
~11 mcg/kg
0ml*
-
Dose Level 2
~22 mcg/kg
0ml*
-
Dose Level 3
~34 mcg/kg
0ml*
-
Dose Level 4
~45 mcg/kg
0ml*
-
Dose Level 5
~56 mcg/kg
0ml*
* Maximum individual dose in this weight range.
Please refer to the SmPC for full dosing information
Request a printed dosing wheel
Submit this form to request a printed dosing wheel to support you or your team:
Clinical Evidence
Glycopyrronium has demonstrated lower rates of side effects2 and treatment cessation2,3 vs. hyoscine.